Perrigo Co PLC (PRGO)

PRGO (NYSE:Drugs) EQUITY
$138.77
pos +0.95
+0.69%
Today's Range: 136.33 - 140.37 | PRGO Avg Daily Volume: 2,253,100
Last Update: 02/09/16 - 4:02 PM EST
Volume: 1,140,293
YTD Performance: -4.75%
Open: $136.91
Previous Close: $137.82
52 Week Range: $135.87 - $215.73
Oustanding Shares: 146,402,066
Market Cap: 21,064,329,256
6-Month Chart
TheStreet Ratings Grade for PRGO
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 6 3
Moderate Buy 0 0 0 0
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.93 2.00 2.08 2.40
Latest Dividend: 0.12
Latest Dividend Yield: 0.35%
Dividend Ex-Date: 11/24/15
Price Earnings Ratio: 148.33
Price Earnings Comparisons:
PRGO Sector Avg. S&P 500
148.33 143.70 28.38
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-15.06% -8.32% 27.26%
GROWTH 12 Mo 3 Yr CAGR
Revenue 13.40 0.45 0.13
Net Income -37.70 -0.67 -0.31
EPS -48.30 -0.79 -0.40
Earnings for PRGO:
EBITDA 1.30B
Revenue 4.60B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $2.28 $2.53 $9.73 $10.83
Number of Analysts 12 12 15 16
High Estimate $2.40 $2.72 $10.00 $11.59
Low Estimate $2.13 $2.40 $9.20 $10.15
Prior Year $1.85 $2.18 $7.35 $9.73
Growth Rate (Year over Year) 23.20% 15.94% 32.33% 11.31%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishPerrigo upgraded at Argus

Dec 10, 2015 | 7:41 AM EST

PRGO was upgraded from Hold to Buy, Argus said. $170 price target. Company can continue to take market share with generic OTC drugs. 

 

By

Carleton English

 | Nov 23, 2015 | 12:00 PM EST

Stand-alone vitamin and supplement shops like GNC and Vitamin Shoppe shares will continue to fall in light of a Justice Department investigation...

By

Bret Jensen

 | Nov 17, 2015 | 9:00 AM EST

These two will continue to churn out earnings growth.

By

Timothy Collins

 | Oct 23, 2015 | 9:30 AM EDT

Buying it here would be like trying to catch a falling knife.

By

Jim Cramer

 | May 21, 2015 | 6:49 PM EDT

Deals coming fast and furious in the best group in town.

By

Jim Cramer

 | May 18, 2015 | 3:24 PM EDT

Acquisitions cut into overabundance of companies.

By

Antonia Oprita

 | Apr 22, 2015 | 5:30 AM EDT

And four other things you need to know now.

By

David Peltier

 | Apr 21, 2015 | 4:49 PM EDT

U.S. stocks were mixed on Tuesday.

By

Jim Cramer

 | Apr 21, 2015 | 3:44 PM EDT

Biotech companies are saying, "I do."

By

Jim Cramer

 | Apr 9, 2015 | 1:58 PM EDT

These companies are the hottest thing going.

A huge and predictable earnings quarter initially sent Disney (DIS) up after hours but the...

$125 million to sell market on close

We have had some text book timing lately....

The big question now is whether or not the positive divergence between ES (Emini S&P 5...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.